|
Journal of Cancer Research and Therapeutics
Medknow Publications on behalf of the Association of Radiation Oncologists of India (AROI)
ISSN: 0973-1482 EISSN: 0973-1482
Vol. 1, No. 2, 2005, pp. 108-110
|
Bioline Code: cr05022
Full paper language: English
Document type: Research Article
Document available free of charge
|
|
Journal of Cancer Research and Therapeutics, Vol. 1, No. 2, 2005, pp. 108-110
en |
A three way complex translocation (4;9;22) in two patients with chronic myelocytic leukemia
Sheth FrennyJ, Sheth JayeshJ, Verhest Alain
Abstract
Chronic myeloid leukemia (CML) is genetically characterized by the reciprocal translocation of chromosome 9 and 22, t(9;22)(q34;q11) which results in the fusion of BCR/ABL gene observed on the derivative chromosome 22 called Philadelphia (Ph′) chromosome. About 5-8% of Philadelphia positive patients with CML show various complex translocations involving third chromosome in addition to chromosome 9 and 22. In present report we discuss two cases with CML referred at our centre. At the time of initial diagnosis and after 9 months of treatment, one of the patients showed 100% presence of Philadelphia positive in bone marrow culture. During follow-up in an accelerated state, his cytogenetic study revealed a complex translocation (4;9;22)(q25;q34;q11) along with an additional Philadelphia and marker chromosome. The second patient showed a complex (4;9;22)(q25;q34;q11) translocation at the time of diagnosis. He was on hydroxyurea and his follow-up cytogenetic study after the course of chemotherapy showed no changes. Further confirmation of complex translocation was done by FISH study using bcr/abl and whole chromosome 9 probes. Though the additional genes involved in complex variant Ph′ rearrangements have not been characterized, both patients are healthy till 3 to 5 years of initial diagnosis. This could be attributed to the benign effect resulted from reciprocal translocation with no loss or gain of the genetic material.
|
|
© Copyright 2005 Journal of Cancer Research and Therapeutics. Alternative site location: http://www.cancerjournal.net/
|
|